Beam Therapeutics enrolling patients in 60 mg cohort, plans FDA engagement on approval path

Beam Therapeutics is enrolling patients in its 60 mg cohort of its BEAM-301 program and plans to engage with the U.S. FDA regarding a potential path to approval, based on recent safety and efficacy data.

Detected & updated continuously · Source: Nebula